GlassScriptPhysician profile
Marcus N Rhem
NPI 1043208358
$1,987.28
in general payments reported to CMS, 2019-2025
16 companies · $632 in 2025
The $632 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $132 · 2021: $136 · 2022: $76.30 · 2023: $373 · 2024: $513 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,030.26 | 2021-2025 | Clareon, Hydrus Microstent, Ngenuity |
| Novartis Pharmaceuticals Corporation | $166.74 | 2019-2023 | |
| New World Medical,INC. | $144.77 | 2021-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Allergan, INC. | $129.99 | 2020-2022 | |
| Abbvie INC. | $128.92 | 2022-2025 | |
| Nova Eye, INC. | $112.81 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $70.38 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $35.75 | 2024-2025 | Tecnis Iol |
| Glaukos Corporation | $28.40 | 2024 | Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Sun Pharmaceutical Industries INC. | $25.99 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $23.32 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $23.21 | 2024 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $18.74 | 2024 | Oxervate |
| Sight Sciences, INC. | $17.07 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $16.15 | 2024 | Vyzulta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $14.78 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Rhem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.